Phase II Clinical Data For Predix Pharmaceuticals's Lead Drug Candidate Show Positive Results In Generalized Anxiety Disorder

LEXINGTON, Mass.--(BUSINESS WIRE)--June 13, 2006--Predix Pharmaceuticals, which recently announced a definitive agreement to merge with EPIX Pharmaceuticals (Nasdaq:EPIX - News), announced today that a Phase II clinical trial of its lead drug candidate, PRX-00023, showed significantly reduced symptoms and was well-tolerated in the 21 patients with generalized anxiety disorder (GAD) participating in the four-week, open-label study. The results are being presented at the 46th Annual New Clinical Drug Evaluation Unit (NCDEU) meeting in Boca Raton, Fla.